| Kevin P Gurney, CRNA | |
|
723 Memorial Street, Prosser, WA 99350 | |
| (509) 786-2222 | |
| (509) 788-6018 |
| Full Name | Kevin P Gurney |
|---|---|
| Gender | Male |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 723 Memorial Street, Prosser, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104037696 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | AP30007751 (Washington) | Primary |
| Entity Name | Prosser Public Hospital District Of Benton County |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306897681 PECOS PAC ID: 6709787872 Enrollment ID: O20040120000974 |
News Archive
ETView today announced that the Korean Food and Drug Administration ("KFDA") has granted pre-market clearance for VivaSight‐SL. With KFDA clearance, ETView plans to immediately initiate market launch of VivaSight‐SL. ETView also announced a distribution agreement with ChinooMTech Company.
Many Democrats consider their health overhaul increasingly politically dicey now, but "are betting that the only thing worse than passing a bill many of them don't like is not passing one at all," the San Francisco Chronicle reports.
MyVytalics, a privately held company, today announced the release of MySleepInsights, a personal genomics app focusing on genes associated with sleep patterns and nutrition.
The new study, published online today by JAMA Dermatology, identifies high risk patients who may benefit from tailored surveillance.
Pfizer Inc. today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months.
› Verified 5 days ago
| Entity Name | Lewis County Hospital District No 1 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205882909 PECOS PAC ID: 6002727385 Enrollment ID: O20040121000814 |
News Archive
ETView today announced that the Korean Food and Drug Administration ("KFDA") has granted pre-market clearance for VivaSight‐SL. With KFDA clearance, ETView plans to immediately initiate market launch of VivaSight‐SL. ETView also announced a distribution agreement with ChinooMTech Company.
Many Democrats consider their health overhaul increasingly politically dicey now, but "are betting that the only thing worse than passing a bill many of them don't like is not passing one at all," the San Francisco Chronicle reports.
MyVytalics, a privately held company, today announced the release of MySleepInsights, a personal genomics app focusing on genes associated with sleep patterns and nutrition.
The new study, published online today by JAMA Dermatology, identifies high risk patients who may benefit from tailored surveillance.
Pfizer Inc. today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months.
› Verified 5 days ago
| Entity Name | Direct Imaging Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689283285 PECOS PAC ID: 6103244934 Enrollment ID: O20200910002932 |
News Archive
ETView today announced that the Korean Food and Drug Administration ("KFDA") has granted pre-market clearance for VivaSight‐SL. With KFDA clearance, ETView plans to immediately initiate market launch of VivaSight‐SL. ETView also announced a distribution agreement with ChinooMTech Company.
Many Democrats consider their health overhaul increasingly politically dicey now, but "are betting that the only thing worse than passing a bill many of them don't like is not passing one at all," the San Francisco Chronicle reports.
MyVytalics, a privately held company, today announced the release of MySleepInsights, a personal genomics app focusing on genes associated with sleep patterns and nutrition.
The new study, published online today by JAMA Dermatology, identifies high risk patients who may benefit from tailored surveillance.
Pfizer Inc. today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months.
› Verified 5 days ago
| Entity Name | Anesthesia Of Washington Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376262808 PECOS PAC ID: 9830575943 Enrollment ID: O20220927002147 |
News Archive
ETView today announced that the Korean Food and Drug Administration ("KFDA") has granted pre-market clearance for VivaSight‐SL. With KFDA clearance, ETView plans to immediately initiate market launch of VivaSight‐SL. ETView also announced a distribution agreement with ChinooMTech Company.
Many Democrats consider their health overhaul increasingly politically dicey now, but "are betting that the only thing worse than passing a bill many of them don't like is not passing one at all," the San Francisco Chronicle reports.
MyVytalics, a privately held company, today announced the release of MySleepInsights, a personal genomics app focusing on genes associated with sleep patterns and nutrition.
The new study, published online today by JAMA Dermatology, identifies high risk patients who may benefit from tailored surveillance.
Pfizer Inc. today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kevin P Gurney, CRNA 6602 Appleview Road, Yakima, WA 98908 Ph: (509) 895-4970 | Kevin P Gurney, CRNA 723 Memorial Street, Prosser, WA 99350 Ph: (509) 786-2222 |
News Archive
ETView today announced that the Korean Food and Drug Administration ("KFDA") has granted pre-market clearance for VivaSight‐SL. With KFDA clearance, ETView plans to immediately initiate market launch of VivaSight‐SL. ETView also announced a distribution agreement with ChinooMTech Company.
Many Democrats consider their health overhaul increasingly politically dicey now, but "are betting that the only thing worse than passing a bill many of them don't like is not passing one at all," the San Francisco Chronicle reports.
MyVytalics, a privately held company, today announced the release of MySleepInsights, a personal genomics app focusing on genes associated with sleep patterns and nutrition.
The new study, published online today by JAMA Dermatology, identifies high risk patients who may benefit from tailored surveillance.
Pfizer Inc. today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months.
› Verified 5 days ago
Benjamin J Passey, Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 723 Memorial St, Prosser, WA 99350 Phone: 801-644-4700 | |
Alan Steen, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 723 Memorial St, Prosser, WA 99350 Phone: 509-786-2222 Fax: 509-786-6612 | |
James Paul Fulton, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 723 Memorial St, Prosser, WA 99350 Phone: 509-786-2222 Fax: 509-786-6612 |